Repository logo
 
Publication

2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes

2023-07-19Journal article Open access
Simple item page
dc.contributor.authorBertoluci, Marcello Casaccia
dc.contributor.authorJúnior, Wellington S. Silva
dc.contributor.authorValente, Fernando
dc.contributor.authorAraujo, Levimar Rocha
dc.contributor.authorLyra, Ruy
dc.contributor.authorCastro, João Jácome de
dc.contributor.authorRaposo, João
dc.contributor.authorMiranda, Paulo Augusto Carvalho
dc.contributor.authorBoguszewski, Cesar Luiz
dc.contributor.authorHohl, Alexandre
dc.contributor.authorDuarte, Rui
dc.contributor.authorSalles, Joao Eduardo Nunes
dc.contributor.authorSilva-Nunes, José
dc.contributor.authorDores, Jorge
dc.contributor.authorMelo, Miguel
dc.contributor.authorSá, João Roberto de
dc.contributor.authorNeves, João Sérgio
dc.contributor.authorMoreira, Rodrigo Oliveira
dc.contributor.authorMalachias, Marcus Vinicius Bolivar
dc.contributor.authorLamounier, Rodrigo Nunes
dc.contributor.authorMalerbi, Domingos Augusto
dc.contributor.authorCalliari, Luís Eduardo
dc.contributor.authorCardoso, Luis Miguel
dc.contributor.authorCarvalho, Maria Raquel
dc.contributor.authorFerreira, Hélder José
dc.contributor.authorNortadas, Rita
dc.contributor.authorTrujilho, Fábio Rogério
dc.contributor.authorLeitão, Cristiane Bauermann
dc.contributor.authorSimões, José Augusto Rodrigues
dc.contributor.authorReis, Mónica Isabel Natal dos
dc.contributor.authorMelo, Pedro
dc.contributor.authorMarcelino, Mafalda
dc.contributor.authorCarvalho, Davide
dc.date.accessioned2023-07-19T15:16:28Z
dc.date.available2023-07-19T15:16:28Z
dc.date.issued2023-07-19
dc.description.abstractBackground The management of antidiabetic therapy in people with type 2 diabetes (T2D) has evolved beyond gly‑ cemic control. In this context, Brazil and Portugal defned a joint panel of four leading diabetes societies to update the guideline published in 2020. Methods The panelists searched MEDLINE (via PubMed) for the best evidence from clinical studies on treating T2D and its cardiorenal complications. The panel searched for evidence on antidiabetic therapy in people with T2D with‑ out cardiorenal disease and in patients with T2D and atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or diabetic kidney disease (DKD). The degree of recommendation and the level of evidence were determined using predefned criteria. Results and conclusions All people with T2D need to have their cardiovascular (CV) risk status stratifed and HbA1c, BMI, and eGFR assessed before defning therapy. An HbA1c target of less than 7% is adequate for most adults, and a more fexible target (up to 8%) should be considered in frail older people. Non-pharmacological approaches are recommended during all phases of treatment. In treatment naïve T2D individuals without cardiorenal complications, metformin is the agent of choice when HbA1c is 7.5% or below. When HbA1c is above 7.5% to 9%, starting with dual therapy is recommended, and triple therapy may be considered. When HbA1c is above 9%, starting with dual therapyt is recommended, and triple therapy should be considered. Antidiabetic drugs with proven CV beneft (AD1) are recommended to reduce CV events if the patient is at high or very high CV risk, and antidiabetic agents with proven efcacy in weight reduction should be considered when obesity is present. If HbA1c remains above tar‑ get, intensifcation is recommended with triple, quadruple therapy, or even insulin-based therapy. In people with T2D.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBertoluci MC, Silva-Júnior WS, Valente F, et al. 2023 UPDATE Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes. Diabetology & Metabolic Syndrome. 2023; 15:160. Doi 10.1186/s13098-023-01121-xpt_PT
dc.identifier.doi10.1186/s13098-023-01121-xpt_PT
dc.identifier.urihttp://hdl.handle.net/10400.6/13388
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBMCpt_PT
dc.relation.publisherversionhttps://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01121-xpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/pt_PT
dc.subjectASCVDpt_PT
dc.subjectAtherosclerotic diseasept_PT
dc.subjectCardiovascular riskpt_PT
dc.subjectChronic kidney diseasept_PT
dc.subjectDKDpt_PT
dc.subjectDiabetes treatmentpt_PT
dc.subjectGuidelinespt_PT
dc.subjectHeart failurept_PT
dc.subjectIschemic heart diseasept_PT
dc.subjectType 2 diabetespt_PT
dc.subjectSGLT2 inhibitorspt_PT
dc.subjectGLP-1 RApt_PT
dc.title2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceReino Unidopt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage160pt_PT
oaire.citation.titleDiabetology & Metabolic Syndromept_PT
oaire.citation.volume15pt_PT
person.familyNameBertoluci
person.familyNameCANCELA DOS SANTOS RAPOSO
person.familyNameMIRANDA
person.familyNameHohl
person.familyNameDuarte
person.familyNameSalles
person.familyNameSilva-Nunes
person.familyNameDores
person.familyNameCorreia de Melo
person.familyNamede Sa
person.familyNameNeves
person.familyNameMalachias
person.familyNameLamounier
person.familyNameCalliari
person.familyNameNortadas
person.familyNameRodrigues Simões
person.familyNameMelo
person.familyNameMarcelino
person.familyNameCarvalho
person.givenNameMarcello
person.givenNameJOAO FILIPE
person.givenNamePAULO AUGUSTO CARVALHO
person.givenNameAlexandre
person.givenNameRui
person.givenNameJoao Eduardo Nunes
person.givenNameJosé António
person.givenNameJorge
person.givenNameMiguel Ângelo
person.givenNameJoao Roberto
person.givenNameJoão Sérgio
person.givenNameMarcus Vinicius Bolivar
person.givenNameRodrigo
person.givenNameLuis Eduardo P.
person.givenNameRita
person.givenNameJosé Augusto
person.givenNamePedro Gonçalo Correia Baptista Soares de
person.givenNameMafalda
person.givenNameDavide
person.identifier495493
person.identifierczzdoawAAAAJ
person.identifier305541
person.identifierL-4695-2016
person.identifier.ciencia-idC810-EBC6-FCD1
person.identifier.ciencia-id211F-55A0-4B63
person.identifier.ciencia-id4B1C-E132-25F0
person.identifier.ciencia-idA315-E9CE-0FD6
person.identifier.ciencia-idEB1B-FB0C-07F5
person.identifier.ciencia-idE419-CED2-38BA
person.identifier.ciencia-id0611-DE13-A2D9
person.identifier.orcid0000-0002-8307-3162
person.identifier.orcid0000-0003-2589-7208
person.identifier.orcid0000-0001-5433-3386
person.identifier.orcid0000-0002-8073-5837
person.identifier.orcid0000-0002-6819-0985
person.identifier.orcid0000-0003-3865-5320
person.identifier.orcid0000-0002-4728-1220
person.identifier.orcid0000-0001-9883-3809
person.identifier.orcid0000-0003-4050-3473
person.identifier.orcid0000-0003-3115-5606
person.identifier.orcid0000-0002-8173-8255
person.identifier.orcid0000-0002-8171-3920
person.identifier.orcid0000-0001-7432-9085
person.identifier.orcid0000-0003-2085-5316
person.identifier.orcid0000-0003-2696-9453
person.identifier.orcid0000-0003-2264-7086
person.identifier.orcid0000-0002-2206-1758
person.identifier.orcid0000-0002-4011-063X
person.identifier.orcid0000-0002-1066-9029
person.identifier.ridC-7571-2018
person.identifier.ridK-7010-2015
person.identifier.scopus-author-id8135032000
person.identifier.scopus-author-id14059938600
person.identifier.scopus-author-id6508177324
person.identifier.scopus-author-id7102354924
person.identifier.scopus-author-id7003851481
person.identifier.scopus-author-id7003862299
person.identifier.scopus-author-id36896116500
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationb179696b-a449-4996-8282-2b6ec20fd9bc
relation.isAuthorOfPublication4efeab0e-1fb2-4810-b010-a8ea5a82fdac
relation.isAuthorOfPublication418cc4a0-e861-4d03-9c59-885bdbb5402b
relation.isAuthorOfPublicationfc9eef90-778e-467b-9353-d63460eb888b
relation.isAuthorOfPublication67f2bf4b-dec6-4c5f-9dd8-329ffcb32361
relation.isAuthorOfPublicationab793bfe-6080-4f5e-9787-dcfbd62dbfac
relation.isAuthorOfPublication7bd6d083-0ae1-4ebd-bd4f-1f00bc25806b
relation.isAuthorOfPublicationec835938-c6ce-4fcd-99f0-aff149614438
relation.isAuthorOfPublicationae71a853-7367-46b5-ba26-7f9374870246
relation.isAuthorOfPublication90feb524-216b-4b03-a24a-095c770ddd26
relation.isAuthorOfPublicationfc260375-ef1b-4f6f-a5de-ccd12e775e33
relation.isAuthorOfPublication6f88ad00-00d6-4d64-a89d-5f7c5780d4fc
relation.isAuthorOfPublication2b49ccbf-2881-4115-a53c-74bc970f6389
relation.isAuthorOfPublication5221ea8b-8707-4f16-9c7f-1bb83ccbd18a
relation.isAuthorOfPublication6bd4b94e-4d31-4f3f-82c9-033e8ad84c6e
relation.isAuthorOfPublication919b504d-aaa9-40ee-a1a5-40e1e0a57f6f
relation.isAuthorOfPublication073d9cc9-3c08-4ebb-9f04-864a4915221e
relation.isAuthorOfPublicationb083d94b-0062-4f6f-9800-f5116bfd745a
relation.isAuthorOfPublication73397933-3944-4ffe-aa37-73d561436d92
relation.isAuthorOfPublication.latestForDiscovery67f2bf4b-dec6-4c5f-9dd8-329ffcb32361

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Bertoluci-2023-UPDATE-Luso-Brazilian-evidence-based-guideline-for-the-management.pdf
Size:
3.17 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCS - DCM | Documentos por Auto-Depósito